専門分野

• 衛生化学
• 薬物代謝学

担当科目

• 衛生薬学III
• 放射化学
• 衛生薬学実習
• 模擬薬局実習
• 生物・衛生・生薬系統合演習
• 薬学応用演習
• 薬学総合演習

メッセージ

• 何事も努力を積み重ねることが自信に繋がります。失敗を活かし、恐れずに大学生活を送ってください。

学歴

• 九州大学大学院 薬学研究科 博士課程 修了(1988)
• 九州大学大学院 薬学研究科 修士課程 修了(1985)
• 東北薬科大学 薬学部 卒業(1982)

学位

• 薬学博士

免許・資格

• 薬剤師

主な職歴

• 2025-
• 姫路獨協大学 薬学部 教授
• 2013-2025
• 横浜薬科大学 薬学部 教授
• 2003-2013
• 岡山大学 薬学部 助教授・准教授
• 1991-2013
• 国立医薬品食品衛生研究所 環境衛生化学部 主任研究官・室長
• 1990-1991
• 九州大学 薬学部 助手
• 1988-1990
• 米国国立衛生研究所(NIH) 国立癌研究所(NCI) 博士研究員

所属学会

• 日本薬学会
• 日本薬物動態学会
• 日本毒性学会

論文・解説

原著論文 (英文)

• Hanioka N*, Isobe T, Saito K, Nagaoka K, Mori Y, Jinno H, Ohkawara S, Tanaka-Kagawa T. Glucuronidation of tizoxanide, an active metabolite of nitazoxanide, in liver and small intestine: Species differences in humans, monkeys, dogs, rats, and mice and responsible UDP-glucuronosyltransferase isoforms in humans. Comp Biochem Physiol C Toxicol Pharmacol 2024;283:109962.
• Hanioka N*, Isobe T, Saito K, Nagaoka K, Mori Y, Jinno H, Ohkawara S, Tanaka-Kagawa T. Hepatic glucuronidation of tetrabromobisphenol A and tetrachlorobisphenol A: interspecies differences in humans and laboratory animals and responsible UDP-glucuronosyltransferase isoforms in humans. Arch Toxicol 2024;98(3):837-848.．
• Isobe T, Ohkawara S, Mori Y, Jinno H, Tanaka-Kagawa T, Hanioka N*. Hydrolysis of dibutyl phthalate and di(2-ethylhexyl) phthalate in human liver, small intestine, kidney, and lung: An in vitro analysis using organ subcellular fractions and recombinant carboxylesterases. Chem Biol Interact 2023;372:110353.
• Mori Y, Tanaka-Kagawa T, Tahara M, Kawakami T, Aoki A, Okamoto Y, Isobe T, Ohkawara S, Hanioka N, Azuma K, Sakai S, Jinno H. Species differences in activation of TRPA1 by resin additive-related chemicals relevant to indoor air quality. J Toxicol Sci 2023;48(1):37-45.
• Mori Y, Aoki A, Okamoto Y, Isobe T, Ohkawara S, Hanioka N, Tanaka-Kagawa T, Jinno H. Species-specific activation of transient receptor potential ankyrin 1 by phthalic acid monoesters. Biol Pharm Bull 2022;45(12):1839-1846.
• Mori Y, Aoki A, Okamoto Y, Isobe T, Ohkawara S, Hanioka N, Tanaka-Kagawa T, Jinno H. Isoform-specific quantification of human bitter taste receptor transcripts using real-time PCR analysis. Biol Pharm Bull 2022;45(8):1185-1190.．
• Hanioka N*, Tanaka-Kagawa T, Mori Y, Ikushiro S, Jinno H, Ohkawara S, Isobe T. Regioselective glucuronidation of flavones at C5, C7, and C4´ positions in human liver and intestinal microsomes: comparison among apigenin, acacetin, and genkwanin. Biol Pharm Bull 2022;45(8):1116-1123.
• Kitaguchi T, Mizota T, Ito M, Ohno K, Kobayashi K, Ogawa I, Qiu S, Iwao T, Hanioka N, Tanaka M, Matsunaga T. Simultaneous evaluation of membrane permeability and UDP-glucuronosyltransferase-mediated metabolism of food-derived compounds using human induced pluripotent stem cell-derived small intestinal epithelial cells. Drug Metab Dispos 2022;50(1):17-23.
• Hanioka N*, Isobe T, Tanaka-Kagawa T, Jinno H, Ohkawara S. In vitro glucuronidation of bisphenol A in liver and intestinal microsomes: interspecies differences in humans and laboratory animals. Drug Chem Toxicol 2022;45(4):1565-1569.
• Hanioka N*, Saito K, Isobe T, Ohkawara S, Jinno H, Tanaka-Kagawa T. Favipiravir biotransformation in liver cytosol: species and sex differences in humans, monkeys, rats, and mice. Biopharm Drug Dispos 2021;42(5):218-225.
• Hanioka N*, Isobe T, Tanaka-Kagawa T, Ohkawara S. Wogonin glucuronidation in liver and intestinal microsomes of humans, monkeys, dogs, rats, and mice. Xenobiotica 2020;50(8):906-912.

• 過去分はこちら

  • Isobe T, Ohkawara S, Ochi S, Tanaka-Kagawa T, Hanioka N*. S-equol glucuronidation in liver and intestinal microsomes of humans, monkeys, dogs, rats, and mice. Food Chem Toxicol 2019;131:110542.
  • Tanaka-Kagawa T, Saito I, Onuki A, Tahara M, Kawakami T, Sakai S, Ikarashi Y, Oizumi S, Chiba M, Uemura H, Miura N, Kawamura I, Hanioka N, Jinno H. Method validation for the determination of phthalates in indoor air by GC-MS with solid-phase adsorption/solvent extraction using octadecyl silica filter and styrene-divinylbenzene copolymer cartridge. BPB Repotrs 2019;2:86-90.
  • Hanioka N*, Isobe T, Ohkawara S, Ochi S, Tanaka-Kagawa T, Jinno H. Hydrolysis of di(2-ethylhexyl) phthalate in humans, monkeys, dogs, rats, and mice: an in vitro analysis using liver and intestinal microsomes. Toxicol In Vitro 2019;54:237-242.
  • Taguchi M, Shigeyama M, Ogawa N, Murata M, Hanioka N, Yamamoto H, Teramachi H. Evaluation of tumor tissue fixation effects of formulation modified Mohs pastes in mice and their water-absorbing properties. Biol Pharm Bull 2018;41(12):1824-1829.
  • Hanioka N*, Ohkawara S, Isobe T, Ochi S, Tanaka-Kagawa T, Jinno H. Regioselective glucuronidation of daidzein in liver and intestinal microsomes of humans, monkeys, rats, and mice. Arch Toxicol 2018;92(9):2809-2817.
  • Isobe T, Ohkawara S, Ochi S, Tanaka-Kagawa T, Jinno H, Hanioka N*. Naringenin glucuronidation in liver and intestine microsomes of humans, monkeys, rats, and mice. Food Chem Toxicol 2018;111:417-422.
  • Miyata-Nozaka Y, Mohd Zain S, Taguchi M, Shigeyama M, Isobe T, Hanioka N*. Carbamazepine 10,11-epoxidation in human liver microsomes: influence of the CYP3A5*3 polymorphism. Pharmazie 2017;72(12):747-450.
  • Isobe T, Ohkawara S, Tanaka-Kagawa T, Jinno H, Hanioka N*. Hepatic glucuronidation of 4-tert-octylphenol in humans: inter-individual variability and responsible UDP-glucuronosyltransferase isoforms. Arch Toxicol 2017;91(11):3543-3550.
  • Hanioka N*, Isobe T, Ohkawara S, Tanaka-Kagawa T, Jinno H. Glucuronidation of 4-tert-octylphenol in humans, monkeys, rats, and mice: an in vitro analysis using liver and intestine microsomes. Arch Toxicol 2017;91(3):1227-1232. Arch Toxicol 2018;92(9):2809-2817.
  • Hanioka N*, Kinashi Y, Tanaka-Kagawa T, Isobe T, Jinno H. Glucuronidation of mono(2-ethylhexyl) phthalate in humans: roles of hepatic and intestinal UDP-glucuronosyltransferases. Arch Toxicol 2017;91(2):689-698.．
  • Hanioka N*, Isobe T, Kinashi Y, Tanaka-Kagawa T, Jinno H. Hepatic and intestinal glucuronidation of mono(2-ethylhexyl) phthalate, an active metabolite of di(2-ethylhexyl) phthalate, in humans, dogs, rats and mice: an in vitro analysis using microsomal fractions. Arch Toxicol 2016;90(7):1651-1657.
  • Kishi N, Takasuka A, Kokawa Y, Isobe T, Taguchi M, Shigeyama M, Murata M, Suno M, Hanioka N*. Raloxifene glucuronidation in liver and intestinal microsomes of humans and monkeys: contribution of UGT1A1, UGT1A8, and UGT1A9. Xenobiotica 2016;46(4):289-295.
  • Miyake Y, Hirose R, Isobe T, Hanioka N*. Molecular cloning and functional analysis of minipig UDP-glucuronosyltransferase 1A6. Xenobiotica 2016;46(3):193-199.
  • Isobe T, Kofuji K, Okada K, Fujimori J, Murata M, Shigeyama M, Hanioka N, Murata Y. Adsorption of histones on natural polysaccharides: the potential as agent for multiple organ failure in sepsis. Int J Biol Macromol 2016:84:54-57.
  • Mukai M, Isobe T, Okada K, Murata M, Shigeyama M, Hanioka N*. Species and sex differences in propofol glucuronidation in liver microsomes of humans, monkeys, rats and mice. Pharmazie 2015;70 (7):466-470.
  • Mukai M, Tanaka S, Yamamoto K, Murata M, Okada K, Isobe T, Shigeyama M, Hichiya H, Hanioka N*. In vitro glucuronidation of propofol in microsomal fractions from human liver, intestine and kidney: tissue distribution and physiological role of UGT1A9. Pharmazie 2014;69(11):829-832.
  • Yamamoto K, Mukai M, Nagaoka K, Hayashi K, Hichiya H, Okada K, Murata M, Shigeyama M, Narimatsu S, Hanioka N*. Functional characterization of cynomolgus monkey UDP-glucuronosyltransferase 1A9. Eur J Drug Metab Pharmacokinet 2014;39(3):195-202. (IF, 2.1), 査読有り．
  • Takahara Y, Kinashi Y, Takahara Y, Hichiya H, Okada K, Murata M, Shigeyama M, Hanioka N*. Butylbenzyl phthalate hydrolysis in liver microsomes of humans, monkeys, dogs, rats and mice. Biol Pharm Bull 2014;37(4):703-706.
  • Kuze J, Mutoh T, Takenaka T, Oda N, Hanioka N, Narimatsu S. Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by CYP3A enzymes via in vivo and in vitro oxidation of midazolam and triazolam. Xenobiotica 2013;43(7):598-606.
  • Kokawa Y, Kishi N, Jinno H, Tanaka-Kagawa T, Narimatsu S, Hanioka N*. Effect of UDP-glucuronosyltransferase 1A8 polymorphism on raloxifene glucuronidation. Eur J Pharm Sci 2013;49(2):199-205.
  • Mayumi K, Hanioka N, Masuda K, Koeda A, Naito S, Miyata A, Narimatsu S. Characterization of marmoset CYP2B6: cDNA cloning, protein expression and enzymatic functions. Biochem Pharmacol 2013;85(8):1182-1194.．
  • Miyake Y, Mayumi K, Jinno H, Tanaka-Kagawa T, Narimatsu S, Hanioka N*. cDNA cloning and functional analysis of minipig UDP-glucuronosyltransferase 1A1. Biol Pharm Bull 2013;36(3):452-461.
  • Hanioka N*, Takahara Y, Takahara Y, Tanaka-Kagawa T, Jinno H, Narimatsu S. Hydrolysis of di-n-butyl phthalate, butylbenzyl phthalate and di(2-ethylhexyl) phthalate in human liver microsomes. Chemosphere 2012;89(9):1112-1117.
  • Nagaoka K, Hanioka N, Ikushiro S, Yamano S, Narimatsu S. The effects of N-glycosylation on the glucuronidation of zidovudine and morphine by UGT2B7 expressed in HEK293 cells. Drug Metab Pharmacokinet 2012;27(4):388-397.
  • Hanioka N*, Nonaka Y, Saito K, Kataoka H, Narimatsu S. Effect of aflatoxin B1 on UDP-glucuronosyltransferase mRNA expression in HepG2 cells. Chemosphere 2012;89(5):526-529.
  • Hanioka N*, Tanaka S, Moriguchi Y, Narimatsu S. Stereoselective glucuronidation of carvedilol in human liver and intestinal microsomes. Pharmacology 2012;90(3-4):117-124.
  • Hanioka N*, Iwabu H, Hanafusa H, Nakada S, Narimatsu S. Expression and inducibility of UDP-glucuronosyltransferase 1As in MCF-7 human breast carcinoma cells. Basic Clin Pharmacol Toxicol 2012;110(3):253-258.
  • Narimatsu S, Nakanishi R, Hanioka N, Saito K, Kataoka H. Characterization of inhibitory effects of perfluorooctane sulfonate on human hepatic cytochrome P450 isoenzymes: focusing on CYP2A6. Chem Biol Interact 2011;194(2-3):120-126.
  • Hanioka N*, Oka H, Nagaoka K, Ikushiro S, Narimatsu S. Effect of UDP-glucuronosyltransferase 2B15 polymorphism on bisphenol A glucuronidation. Arch Toxicol 2011;85(11):1373-1381.
  • Hanioka N*, Matsumoto K, Saito Y, Narimatsu S. Influence of CYP2C8*13 and CYP2C8*14 alleles on amiodarone N-deethylation. Basic Clin Pharmacol Toxicol 2011;108(5):359-362.
  • Narimatsu S, Nakata T, Shimizudania T, Nagaoka K, Nakura H, Masuda K, Katsu T, Koeda A, Naito S, Yamano S, Miyata A, Hanioka N. Regio- and stereoselective oxidation of propranolol enantiomers by human CYP2D6, cynomolgus monkey CYP2D17 and marmoset CYP2D19. Chem Biol Interact 2011;189(3):146-152.
  • Ishizaki A, Saito K, Hanioka N, Narimatsu S, Kataoka H. Determination of polycyclic aromatic hydrocarbons in food samples by automated on-line in-tube solid-phase microextraction coupled with high-performance liquid chromatography-fluorescence detection. J Chromatogr A 2010;1217(35):5555-5563.
  • Hanioka N*, Tanabe N, Jinno H, Tanaka-Kagawa T, Nagaoka K, Naito S, Koeda A, Narimatsu S. Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci 2010;87(7-8):261-268.
  • Hanioka N*, Matsumoto K, Saito Y, Narimatsu S. Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel. Basic Clin Pharmacol Toxicol 2010;107(1):565-569.
  • Hanioka N*, Yamamoto M, Tanaka-Kagawa T, Jinno H, Narimatsu S. Functional characterization of human cytochrome P450 2E1 allelic variants: in vitro metabolism of benzene and toluene by recombinant enzymes expressed in yeast cells. Arch Toxicol 2010;84(5):363-371.
  • Shimizudani T, Nagaoka K, Hanioka N, Yamano S, Narimatsu S. Comparative study of the oxidation of propranolol enantiomers in hepatic and small intestinal microsomes from cynomolgus and marmoset monkeys. Chem Biol Interact 2010;183(1): 67-78.
  • Kuze J, Mutoh T, Takenaka T, Morisaki K, Nakura H, Hanioka N, Narimatsu S. Separate evaluation of intestinal and hepatic metabolism of three benzodiazepines in rats with cannulated portal and jugular veins: comparison with the profile in non-cannulated mice. Xenobiotica 2009;39(11):871-880.
  • Nonaka Y, Saito K, Hanioka N, Narimatsu S, Kataoka H. Determination of aflatoxins in food samples by automated on-line in-tube solid-phase microextraction coupled with liquid chromatography-mass spectrometry. J Chromatogr A 2009;1216(20):4416-4422.
  • Maekawa K, Yoshimura T, Saito Y, Fujimura Y, Aohara F, Emoto C, Iwasaki K, Hanioka N, Narimatsu S, Niwa T, Sawada J. Functional characterization of CYP3A4.16: Catalytic activities toward midazolam and carbamazepine. Xenobiotica 2009;39(2):140-147.
  • Narimatsu S, Kazamori D, Masuda K, Katsu T, Funae Y, Naito S, Nakura H, Yamano S, Hanioka N. The mechanism causing the difference in kinetic properties between rat CYP2D4 and human CYP2D6 in the oxidation of dextromethorphan and bufuralol. Biochem Pharmacol 2009;77(5):920-931.
  • Hanioka N*, Naito T, Narimatsu S. Human UDP-glucuronosyltransferase isoforms involved in bisphenol A glucuronidation. Chemosphere 2008;74(1):33-36.
  • Hanioka N*, Hayashi K, Shimizudani T, Nagaoka K, Koeda A, Naito S, Narimatsu S. Stereoselective glucuronidation of propranolol in human and cynomolgus monkey liver microsomes: the role of human hepatic UDP-glucuronosyltransferase isoforms, UGT1A9, UGT2B4 and UGT2B7. Pharmacology 2008;82(4):293-303.
  • Katsu T, Tsunamoto Y, Hanioka N, Komagoe K, Masuda K, Narimatsu S. A caffeine-sensitive membrane electrode: previous misleading report and present approach. Anal Chim Acta 2008;620(1-2):50-54.
  • Hanioka N*, Takeda Y, Tanaka-Kagawa T, Hayashi K, Jinno H, Narimatsu S. Interaction of bisphenol A with human UDP-glucuronosyltransferase 1A6 enzyme. Environ Toxicol 2008;23(3):407-412.
  • Hanioka N*, Tsuneto Y, Saito Y, Maekawa K, Sawada J, Narimatsu S. Influence of CYP2C19*18 and CYP2C19*19 alleles on omeprazole 5-hydroxylation: in vitro functional analysis of recombinant enzymes expressed in Saccharomyces cerevisiae. Basic Clin Pharmacol Toxicol 2008;102(4):388-393.
  • Narimatsu S, Kiryu K, Yonemoto R, Yoshino M, Kobatake M, Kazamori D, Hagino S, Masuda K, Katsu T, Asanuma M, Kumamoto T, Ishikawa T, Funae Y, Yamano S, Hanioka N, Naito S. The roles of amino acid residues at positions 216 and 219 in the structural stability and metabolic functions of rat cytochrome P450 2D1 and 2D2. Chem Biol Interact 2008;172(1):11-21.
  • Narimatsu S, Yonemoto R, Masuda K, Katsu T, Asanuma M, Kamata T, Katagi M, Tsuchihashi H, Kumamoto T, Ishikawa T, Naito S, Yamano S, Hanioka N. Oxidation of 5-methoxy-N,N-diisopropyltryptamine in rat liver microsomes and recombinant cytochrome P450 enzymes. Biochem Pharmacol 2008;75(3):752-760.
  • Hanioka N*, Yamamoto M, Iwabu H, Jinno H, Tanaka-Kagawa T, Naito S, Shimizu T, Masuda K, Katsu T, Narimatsu S. Functional characterization of human and cynomolgus monkey cytochrome P450 2E1 enzymes. Life Sci 2007;81(19-20):1436-1445.
  • Saito K, Dan H, Masuda K, Katsu T, Hanioka N, Yamamoto S, Miyano K, Yamano S, Narimatsu S. Stereoselective hexobarbital 3´-hydroxylation by CYP2C19 expressed in yeast cells and the roles of amino acid residues at positions 300 and 476. Chirality 2007;19(7):550-558.
  • Hanioka N*, Tsuneto Y, Saito Y, Sumada T, Maekawa K, Saito K, Sawada J, Narimatsu S. Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population. Xenobiotica 2007;37(4):342-355.
  • Katsu T, Tsunamoto Y, Hanioka N, Komagoe K, Masuda K, Narimatsu S. S,S,S-Tris(2-ethylhexyl) phosphorotrithioate as an effective solvent mediator for a mexiletine-sensitive membrane electrode. Anal Bioanal Chem 2007;387(6):2057-2064.
  • Narimatsu S, Torigoe F, Tsuneto Y, Saito K, Hanioka N, Masuda K, Katsu T, Yamamoto S, Yamano S, Baba T, Miyata A. Cloning of a cDNA encoding a novel marmoset CYP2C enzyme, expression in yeast cells and characterization of its enzymatic functions. Biochem Pharmacol 2006;72(12):1738-1748.
  • Hanioka N*, Takeda Y, Jinno H, Tanaka-Kagawa T, Naito S, Koeda A, Shimizu T, Nomura M, Narimatsu S. Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A6 enzymes. Chem Biol Interact 2006;164(1-2):136-145.
  • Hanioka N*, Obika N, Nishimura M, Jinno H, Tanaka-Kagawa T, Saito K, Kiryu K, Naito S, Narimatsu S. Inducibility of UDP-glucuronosyltransferase 1As by β-naphthoflavone in HepG2 cells. Food Chem Toxicol 2006;44(8):1251-1260.
  • Ueda K, Yonemoto R, Komagoe K, Masuda K, Hanioka N, Narimatsu S, Katsu T. Tris(2-ethylhexyl)phosphine oxide as an effective solvent mediator for constructing a serotonin-selective membrane electrode. Anal Chim Acta 2006;565(1):36-41.
  • Hanioka N*, Okumura Y, Saito Y, Hichiya H, Soyama A, Saito K, Ueno K, Sawada J, Narimatsu S. Catalytic roles of CYP2D6.10 and CYP2D6.36 enzymes in mexiletine metabolism: in vitro functional analysis of recombinant proteins expressed in Saccharomyces cerevisiae. Biochem Pharmacol 2006;71(9):1386-1395.
  • Narimatsu S, Yonemoto R, Saito K, Takaya K, Kumamoto T, Ishikawa T, Asanuma M, Funada M, Kiryu K, Naito S, Yoshida Y, Yamamoto S, Hanioka N. Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes. Biochem Pharmacol 2006;71(9):1377-1385.
  • Masuda K, Tamagake K, Katsu T, Torigoe F, Saito K, Hanioka N, Yamano S, Yamamoto S, Narimatsu S. Roles of phenylalanine at position 120 and glutamic acid at position 222 in the oxidation of chiral substrates by cytochrome P450 2D6. Chirality 2006;18(3):167-176.．
  • Narimatsu S, Takatsu N, Yamano S, Inoue Y, Hanioka N, Kiryu K, Naito S, Gonzalez FJ, Yamamoto S. The effect of dimethyl sulfoxide on the function of cytochrome P450 2D6 in HepG2 cells upon the co-expression with NADPH-cytochrome P450 reductase. Chem Biol Interact 2006;159(1):47-57.
  • Saito Y, Hanioka N, Maekawa K, Isobe T, Tsuneto Y, Nakamura R, Soyama A, Ozawa S, Tanaka-Kagawa T, Jinno H, Narimatsu S, Sawada J. Functional analysis of three CYP1A2 variants found in a Japanese population. Drug Metab Dispos 2005;33(12):1905-1910.
  • Isobe T, Hichiya H, Hanioka N, Yamamoto S, Shinoda S, Funae Y, Satoh T, Yamano S, Narimatsu S. Different effects of desipramine on bufuralol 1´-hydroxylation by rat and human CYP2D enzymes. Biol Pharm Bull 2005;28(4):634-640.
  • Soyama A, Saito Y, Hanioka N, Maekawa K, Komamura K, Kamakura S, Kitakaze M, Tomoike H, Ueno K, Goto Y, Kimura H, Katoh M, Sugai K, Saitoh O, Kawai M, Ohnuma T, Ohtsuki T, Suzuki C, Minami N, Kamatani N, Ozawa S, Sawada J. Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab Pharmacokinet 2005;20(1):24-33.
  • Narimatsu S, Oda M, Hichiya H, Isobe T, Asaoka K, Hanioka N, Yamano S, Shinoda S, Yamamoto S. Molecular cloning and functional analysis of cytochrome P450 1A2 from Japanese monkey liver: comparison with marmoset cytochrome P450 1A2. Chem Biol Interact 2005;152(1):1-12.
  • Miyano J, Yamamoto S, Hanioka N, Narimatsu S, Ishikawa T, Ogura K, Watabe T, Nishimura M, Ueda N, Naito S. Involvement of SULT1A3 in elevated sulfation of 4-hydroxypropranolol in HepG2 cells pretreated with β-naphthoflavone. Biochem Pharmacol 2005;69(6):941-950.
  • Masuda K, Tamagake K, Okuda Y, Torigoe F, Tsuzuki D, Isobe T, Hichiya H, Hanioka N, Yamamoto S, Narimatsu S. Change in enantioselectivity in bufuralol 1´-hydroxylation by the substitution of phenylalanine-120 by alanine in cytochrome P450 2D6. Chirality 2005;17(1):37-43.
  • Narimatsu S, Imoto K, Isobe T, Kiryu K, Naito S, Hichiya H, Funae Y, Hanioka N, Yamamoto S. The roles of amino acid residues at positions 43 and 45 in microsomal contents and enzymatic functions of rat CYP2D1 and CYP2D2. Biochem Biophys Res Commun 2004;324(2):627-633.
  • Masuda K, Hashimoto H, Tamagake K, Okuda Y, Tsuzuki D, Isobe T, Hichiya H, Hanioka N, Yamamoto S, Narimatsu S. Changes in the enzymatic properties of CYP2D6 by the substitution of phenylalanine at position 120 by alanine. J Health Sci 2004;50(5):503-510.
  • Hichiya H, Kuramoto S, Yamamoto S, Shinoda S, Hanioka N, Narimatsu S, Asaoka K, Miyata A, Iwata S, Nomoto M, Satoh T, Kiryu K, Ueda N, Naito S, Tucker GT, Ellis SW. Cloning and functional expression of a novel marmoset cytochrome P450 2D enzyme, CYP2D30: comparison with the known marmoset CYP2D19. Biochem Pharmacol 2004;68(1):165-175.
  • Jinno H, Tanaka-Kagawa T, Hanioka N, Ishida S, Saeki M, Soyama A, Itoda M, Nishimura T, Saito Y, Ozawa S, Ando M, Sawada J. Identification of novel alternative splice variants of human constitutive androstane receptor and characterization of their expression in the liver. Mol Pharmacol 2004;65(3):496-502.
  • Ohno A, Saito Y, Hanioka N, Jinno H, Saeki M, Ando M, Ozawa S, Sawada J. Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol. Drug Metab Dispos 2004;32(2):235-239.
  • Tanaka-Kagawa T, Hanioka N, Yoshida H, Jinno H, Ando M. Arsenite and arsenate activate extracellular signal-regulated kinases 1/2 by an epidermal growth factor receptor-mediated pathway in normal human keratinocytes. Br J Dermatol 2003;149(6):1116-1127.
  • Jinno H, Saeki M, Saito Y, Tanaka-Kagawa T, Hanioka N*, Sai K, Kaniwa N, Ando M, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Ozawa S, Sawada J. Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients. J Pharmacol Exp Ther 2003;306(2):688-693.
  • Hanioka N*, Tanaka-Kagawa T, Miyata Y, Matsushima E, Makino Y, Ohno A, Yoda R, Jinno H, Ando M. Functional characterization of three human cytochrome P450 2E1 variants with amino acid substitutions. Xenobiotica 2003;33(6):575-586.
  • Jinno H, Saeki M, Tanaka-Kagawa T, Hanioka N*, Saito Y, Ozawa S, Ando M, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Sawada J. Functional characterization of wild-type and variant (T202I and M59I) human UDP-glucuronosyltransferase 1A10. Drug Metab Dispos 2003;31(5):528-532.
  • Maekawa K, Itoda M, Hanioka N, Saito Y, Murayama N, Nakajima O, Soyama A, Ishida S, Ozawa S, Ando M, Sawada J. Non-synonymous single nucleotide alterations in the microsomal epoxide hydrolase gene and their functional effects. Xenobiotica 2003;33(3):277-287.
  • Jinno H, Tanaka-Kagawa T, Ohno A, Makino Y, Matsushima E, Hanioka N*, Ando M. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 2003 ;31(4):398-403.
  • Tanaka-Kagawa T, Jinno H, Hasegawa T, Makino Y, Seko Y, Hanioka N, Ando M. Functional characterization of two variant human GSTO 1-1s (Ala140Asp and Thr217Asn). Biochem Biophys Res Commun 2003;301(2):516-520.
  • Jinno H, Tanaka-Kagawa T, Hanioka N*, Saeki M, Ishida S, Nishimura T, Ando M, Saito Y, Ozawa S, Sawada J. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos 2003;31(1):108-113.
  • Soyama A, Hanioka N*, Saito Y, Murayama N, Ando M, Ozawa S, Sawada J. Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A. Pharmacol Toxicol 2002;91(4):174-178.
  • Hanioka N*, Saito Y, Soyama A, Ando M, Ozawa S, Sawada J. High-performance liquid chromatographic assay for amiodarone N-deethylation activity in human liver microsomes using solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2002;774(1):105-113.
  • Hanioka N*, Ozawa S, Jinno H, Tanaka-Kagawa T, Nishimura T, Ando M, Sawada J. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. Drug Metab Dispos. 2002;30(4):391-396.
  • Hanioka N*, Watanabe K, Yoda R, Ando M. Effect of alachlor on hepatic cytochrome P450 enzymes in rats. Drug Chem Toxicol 2002;25(1):25-37.
  • Soyama A, Saito Y, Hanioka N, Murayama N, Nakajima O, Katori N, Ishida S, Sai K, Ozawa S, Sawada J. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol Pharm Bull 2001;24(12):1427-1430.
  • Hanioka N*, Ozawa S, Jinno H, Ando M, Saito Y, Sawada J. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica 2001;31(10):687-999.
  • Hanioka N*, Jinno H, Nishimura T, Ando M, Ozawa S, Sawada J. High-performance liquid chromatographic assay for glucuronidation activity of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in human liver microsomes. Biomed Chromatogr 2001;15(5):328-333.
  • Hanioka N*, Jinno H, Tanaka-Kagawa T, Nishimura T, Ando M. Determination of UDP-glucuronosyltransferase UGT1A6 activity in human and rat liver microsomes by HPLC with UV detection. J Pharm Biomed Anal 2001;25(1):65-75.
  • Hanioka N*, Tatarazako N, Jinno H, Arizono K, Ando M. Determination of cytochrome P450 1A activities in mammalian liver microsomes by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 2000;744(2):399-406.
  • Hanioka N*, Tanaka-Kagawa T, Chung YS, Nishimura T, Jinno H, Ando M. Changes in hepatic cytochrome P450 enzymes by biodegradation products of 4-tert-octylphenol polyethoxylate in rats. Bull Environ Contam Toxicol 2000;64(6):804-810.
  • Hanioka N*, Jinno H, Tanaka-Kagawa T, Nishimura T, Ando M. Interaction of bisphenol A with rat hepatic cytochrome P450 enzymes. Chemosphere 2000;41(7):973-978.
  • Hanioka N*, Jinno H, Chung YS, Nishimura T, Tanaka-Kagawa T, Ando M. Effect of 4-tert-octylphenol on cytochrome P450 enzymes in rat liver. Arch Toxicol 2000;73(12):625-631.
  • Hanioka N*, Jinno H, Tanaka-Kagawa T, Nishimura T, Ando M. In vitro metabolism of simazine, atrazine and propazine by hepatic cytochrome P450 enzymes of rat, mouse and guinea pig, and oestrogenic activity of chlorotriazines and their main metabolites. Xenobiotica 1999;29(12):1213-1226.
  • Hanioka N*, Jinno H, Chung YS, Tanaka-Kagawa T, Nishimura T, Ando M. Inhibition of rat hepatic cytochrome P450 activities by biodegradation products of 4-tert-octylphenol ethoxylate. Xenobiotica 1999;29(9):873-883.
  • Hanioka N*, Jinno H, Tanaka-Kagawa T, Nishimura T, Ando M. In vitro metabolism of chlorotriazines: characterization of simazine, atrazine, and propazine metabolism using liver microsomes from rats treated with various cytochrome P450 inducers. Toxicol Appl Pharmacol 1999;156(3):195-205.
  • Jinno H, Hatakeyama N, Hanioka N, Yoda R, Nishimura T, Ando M. Cytotoxic and porphyrinogenic effects of diphenyl ethers in cultured rat hepatocytes: chlornitrofen (CNP), CNP-amino, chlomethoxyfen and bifenox. Food Chem Toxicol 1999;37(1):69-74.
  • Hanioka N*, Jinno H, Kitazawa K, Tanaka-Kagawa T, Nishimura T, Ando M, Ogawa K. In vitro biotransformation of atrazine by rat liver microsomal cytochrome P450 enzymes. Chem Biol Interact 1998;116(3):181-198.
  • Hanioka N*, Jinno H, Tanaka-Kagawa T, Nishimura T, Ando M. Changes in rat liver cytochrome P450 enzymes by atrazine and simazine treatment. Xenobiotica 1998;28(7):683-698.
  • Hanioka N*, Jinno H, Nishimura T, Ando M. Suppression of male-specific cytochrome P450 isoforms by bisphenol A in rat liver. Arch Toxicol 1998;72(7):387-394.
  • Hanioka N*, Jinno H, Nishimura T, Ando M. Changes in hepatic cytochrome P450 enzymes by cis– and trans-1,2-dichloroethylenes in rat. Xenobiotica 1998;28(1):41-51.
  • Hanioka N*, Jinno H, Nishimura T, Ando M. Changes in cytochrome P450 enzymes by 1,1-dichloroethylene in rat liver and kidney. Arch Toxicol 1997;72(1):9-16.
  • Jinno H, Hanioka N, Takahashi A, Nishimura T, Toyo’oka T, Ando M. Comparative cytotoxicity of the aqueous chlorination products of thiobencarb, a thiocarbamate herbicide, in cultured rat hepatocytes. Toxicol In Vitro 1997;11(6):731-739.
  • Jinno H, Hanioka N, Nishikawa S, Yoda R, Toyo’oka T, Nishimura T, Ando M. Hepatotoxicity of diisopropyl ester of malonic acid and chloromalonic acids, disinfection by-products of the fungicide isoprothiolane. Arch Toxicol 1997;71(9):550-555.
  • Jinno H, Hanioka N, Onodera S, Nishimura T, Ando M. Irgasan DP 300 (5-chloro-2-(2,4-dichlorophenoxy)-phenol) induces cytochrome P450s and inhibits haem biosynthesis in rat hepatocytes cultured on Matrigel. Xenobiotica 1997;27(7):681-692.
  • Hanioka N*, Omae E, Yoda R, Jinno H, Nishimura T, Ando M. Effect of trichloroethylene on cytochrome P450 enzymes in the rat liver. Bull Environ Contam Toxicol 1997;58(4):628-635.
  • Hanioka N*, Jinno H, Nishimura T, Ando M. Effect of 2,4,4′-trichloro-2′-hydroxydiphenyl ether on cytochrome P450 enzymes in the rat liver. Chemosphere 1997;34(4):719-730.
  • Hanioka N*, Omae E, Nishimura T, Jinno H, Onodera S, Yoda R, Ando M. Interaction of 2,4,4′-trichloro-2′-hydroxydiphenyl ether with microsomal cytochrome P450-dependent monooxygenases in rat liver. Chemosphere 1996 ;33(2):265-276.
  • Hanioka N*, Hamamura M, Kakino K, Ogata H, Jinno H, Takahashi A, Nishimura T, Ando M. Dog liver microsomal P450 enzyme-mediated toluene biotransformation. Xenobiotica 1995;25(11):1207-1217.
  • Hanioka N*, Nakano K, Jinno H, Hamamura M, Takahashi A, Yoda R, Nishimura T, Ando M. Induction of hepatic drug-metabolizing enzymes by chlornitrofen (CNP) and CNP-amino in rats and mice. Chemosphere 1995;30(7):1297-1309.
  • Hanioka N*, Jinno H, Takahashi A, Nakano K, Yoda R, Nishimura T, Ando M. Interaction of tetrachloroethylene with rat hepatic microsomal P450-dependent monooxygenases. Xenobiotica 1995;25(2):151-165.
  • Hanioka N*, Jinno H, Toyo’oka T, Nishimura T, Ando M. Induction of rat liver drug-metabolizing enzymes by tetrachloroethylene. Arch Environ Contam Toxicol 1995;28(3):273-280.
  • Hanioka N*, Jinno H, Toyo’oka T, Ando M. The effect of 1,2,3,4-tetrachlorodibenzo-p-dioxin on drug-metabolizing enzymes in the rat liver. Chemosphere 1994;29(12):2477-2491.
  • Hanioka N*, Jinno H, Toyo’oka T, Sekita H, Ando M, Kojima S, Takeda M. Effect of subchronic oral treatment with terbium on gastrointestinal uptake of calcium and phosphorus. Bull Environ Contam Toxicol 1994;53(5):663-668.
  • Hanioka N*, Jinno H, Toyo’oka T, Ando M. Effect of 1,2,4-trichlorodibenzo-p-dioxin on drug-metabolizing enzymes in the rat liver. Chemosphere 1994;29(6):1313-1324.
  • Toyo’oka T, Liu YM, Hanioka N, Jinno H, Ando M, Imai K. Resolution of enantiomers of alcohols and amines by high-performance liquid chromatography after derivatization with a novel fluorescent chiral reagent. J Chromatogr A 1994;675(1-2):79-88.
  • Hanioka N*, Jinno H, Toyo’oka T, Kojima S, Ando M. Effect of chlorinated dibenzo-p-dioxins on 7-ethoxycoumarin O-deethylase activity in rat liver microsomes. Chemosphere 1994;28(9):1589-1598.
  • Toyo’oka T, Liu YM, Jinno H, Hanioka N, Ando M, Imai K. Chiral separation of amines by high-performance liquid chromatography after tagging with 4-(N,N-dimethylaminosulphonyl)-7-(2-chloroformylpyrrolidin-1-yl)-2,1,3-benzoxadiazole. Biomed Chromatogr 1994;8(2):85-89.
  • Toyo’oka T, Liu YM, Hanioka N, Jinno H, Ando M. Detrmination of alcohols and amines, labelled with 4-(N,N-dimethylaminosulfonyl)-7-(2-chloroformylpyrrolidin-1-yl)-2,1,3-benzoxadiazole, by liquid chromatography with conventional and laser-induced fluorescence detection. Analytica Chimica Acta 1994;285(3),343-351.
  • Koga N, Shin’yama A, Ishida C, Hanioka N, Yoshimura H. A new metabolite of 2,4,3′,4′-tetrachlorobiphenyl in rat feces. Chem Pharm Bull 1992;40(12):3338-3339.
  • Hanioka N, Gonzalez FJ, Lindberg NA, Liu G, Korzekwa KR. Chimeric cDNA expression and site-directed mutagenesis studies of cytochrome P450s CYP2A1 and CYP2A2. J Steroid Biochem Mol Biol 1992;43(8):1037-1043.
  • Hanioka N, Gonzalez FJ, Lindberg NA, Liu G, Gelboin HV, Korzekwa KR. Site-directed mutagenesis of cytochrome P450s CYP2A1 and CYP2A2: influence of the distal helix on the kinetics of testosterone hydroxylation. Biochemistry 1992;31(13):3364-3370.
  • Ishida C, Koga N, Hanioka N, Saeki HK, Yoshimura H. Metabolism in vitro of 3,4,3′,4′- and 2,5,2′,5′-tetrachlorobiphenyl by rat liver microsomes and highly purified cytochrome P-450. J Pharmacobiodyn 1991;14(5):276-284.
  • Kuo CK, Hanioka N, Hoshikawa Y, Oguri K, Yoshimura H. Species difference of site-selective glucuronidation of morphine. J Pharmacobiodyn 1991;14(4):187-193.
  • Hanioka N, Hoshikawa Y, Mitsui T, Oguri K, Yoshimura H. Species difference in codeine uridine diphosphate-glucuronyltransferase activity of liver microsomes. J Pharmacobiodyn 1990;13(11):712-717.
  • Hanioka N, Kimura S, Meyer UA, Gonzalez FJ. The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934 ® A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am J Hum Genet 1990;47(6):994-1001.
  • Hanioka N, Korzekwa KR, Gonzalez FJ. Sequence requirements for cytochromes P450IIA1 and P450IIA2 catalytic activity: evidence for both specific and non-specific substrate binding interactions through use of chimeric cDNAs and cDNA expression. Protein Eng 1990;3(7):571-575.
  • Oguri K, Hanioka N, Yoshimura H. Species differences in metabolism of codeine: urinary excretion of codeine glucuronide, morphine-3-glucuronide and morphine-6-glucuronide in mice, rats, guinea pigs and rabbits. Xenobiotica 1990;20(7):683-688.
  • Kimura S, Hanioka N, Matsunaga E, Gonzalez FJ. The rat clofibrate-inducible CYP4A gene subfamily. I. Complete intron and exon sequence of the CYP4A1 and CYP4A2 genes, unique exon organization, and identification of a conserved 19-bp upstream element. DNA 1989;8(7):503-516.
  • Matsunaga T, Nagata K, Hanioka N, Tanaka E, Buppodom P, Oguri K, Yoshimura H. Suppressive effect of interferon inducer, polyriboinosinic acid-polyribocytidylic acid on induction of uridine diphosphate-glucuronyltransferases and monooxygenases in liver microsomes of rats. J Pharmacobiodyn 1986;9(4):421-427.
  • Kawashima Y, Hanioka N, Kozuka H. Induction of microsomal stearoyl-CoA desaturase by the administration of various phenoxyacetic acid derivatives. J Pharmacobiodyn 1984;7(5):286-293.
  • Kawashima Y, Hanioka N, Matsumura M, Kozuka H. Induction of microsomal stearoyl-CoA desaturation by the administration of various peroxisome proliferators. Biochim Biophys Acta 1983;752(2):259-264.

原著論文(和文)

• 田口真穂，重山昌人，伊東奈保美，小川法子，高橋知里，村田実希郎，埴岡伸光，山本浩充，寺町ひとみ．デンプン非含有Mohsペーストの調製と製剤評価．薬学雑誌 2017;137(4):477-484.
• 山本浩充，小林万里，芳賀吏那子，伊東奈保美，小川法子，田口真穂，高橋千里，礒部隆史，埴岡伸光，村田実希郎，岡田賢二，重山昌人．がん切除手術に用いられるMohsペーストに関する製剤学的研究．薬剤学 2015;75(4):264-270.
• 神野透人，鈴木敏男，加藤寛久，羽生努，埴岡伸光，豊岡利正，安藤正典．60種類の揮発性有機化合物の相対保持値と保持指標．水道協会雑誌 1994;63:29-37.
• 埴岡伸光*，神野透人, 関田寛, 豊岡利正, 安藤正典, 小嶋茂雄, 武田明治. ランタン連続経口投与ラットにおけるカルシウムおよびリンの代謝について．衛生化学 1994;40(1):26-33.
• 加藤寛久，刑大栄，平田綾子，神野透人，埴岡伸光，安藤正典，小嶋茂雄．パージ・トラップ/ガスクロマトグラフ/質量分析計（GC/MS）法による揮発性有機化合物の多成分一斉分析法の検討．水道協会雑誌 1993;62(9):41-50.
• 埴岡伸光,佐伯和枝エレーナ,石田忠三,古賀信幸,吉村英敏．2,5,2′,5′-tetrachlorobiphenylとその主代謝物3-hydroxy-2,5,2′,5′-tetrachlorobiphenyのラットに対する毒性評価. 福岡医学雑誌 1991;82(5):191-196.

総説(英文)

• Jinno H, Hanioka N, Tanaka-Kagawa T, Saito Y, Ozawa S, Sawada J. Transfection assays with allele-specific constructs: functional analysis of UDP-glucuronosyltransferase variants. Methods Mol Biol 2005;311:19-29.
• Hanioka N*, Jinno H, Nishimura T. Ando M. Effect of chlorinated dibenzo-p-dioxins on drug-metabolizing enzymes in the rat liver. Organohalogen Compd 1994;21:285-289.
• Yoshimura H. Ishida C. Hanioka N, Koga N. Metabolic and toxicological studies on PCBs and related compounds. In: Hodgson E, Michael, R, Motoyama N, editors. Pesticides and the future: toxicological studies of risk and benefits. Reviews IN Pesticide Toxicology (1) 1991;73-82.

総説(和文)

• 成松鎭雄，埴岡伸光，山本重雄．遺伝子多型性Phase I 及びPhase II 薬物代謝酵素を構成要素とした副作用発現予測系の構築．臨床薬理の進歩2007別冊（財団法人臨床薬理研究振興財団）2007;65-81.
• 西村哲治，神野透人，埴岡伸光，安藤正典．簡易毒性試験と個体毒性．アニテックス 1994;7:16-21.

著書・翻訳書

• 埴岡伸光．コンパス衛生薬学：健康と環境 改訂第4版（編集：山本千夏，藤原泰之），担当：第12章（化学物質の毒性（pp.347-373）），南江堂（2025）．
• 埴岡伸光．コンパス衛生薬学：健康と環境 改訂第3版（編集：鍛冶利幸，佐藤雅彦），担当：第12章（化学物質の毒性（pp.343-363）），南江堂（2020）．
• 埴岡伸光．衛生薬学新論（編集：新井洋由，成松鎭雄，山田英之），担当：第4章（疾病予防と健康管理（pp.126-145））；第11章（化学物質と毒性（pp.126-145）），南山堂（2012）．
• 埴岡伸光，安藤正典．上水試験方法解説編（編集：安藤正典），担当：第6章（有機物（pp.446-504）），日本水道協会（2001）．
• 埴岡伸光，神野透人．衛生試験法・注解2000（編集：日本薬学会），担当：第4章（環境試験法：水質試験法（pp.681-868）），金原出版（2000）．
• 相沢貴子，埴岡伸光，安藤正典，神野透人．WHO飲料水水質ガイドライン（第2巻）（編集：眞柄泰基），担当：第14章（有機物質（pp.356-537）），日本水道協会（1999）．
• 埴岡伸光，神野透人．バイオアッセイ-水環境のリスク管理（編集：鈴木基之，内海英雄），担当：第2章（化審法での毒性試験（pp.55-70）），講談社サイエンティフィック（1996）．
• 埴岡伸光，安藤正典，神野透人．飲料水中の各種化学物質の健康影響評価（Ⅲ農薬）：健康に関する勧告集（編集：眞柄泰基），担当：第5章（除草剤（pp.35-94）），日本水道協会（1994）．

特許

• 薬物代謝酵素CYP1A2遺伝子の多型を検出するプライマーセッﾄ、プライマー及びプローブ、並びに該酵素の代謝活性検査薬及びその検査方法）：澤田純一，小澤正吾，斎藤嘉朗，前川京子，成松鎭雄，埴岡伸光（特願2005-187979（2005年6月28日出願）；特開2007-006713（2007年1月18日公開）．
• 代謝酵素CYP2C8の多型を利用した、薬物代謝の検査方法および検査薬並びに薬物代謝を改善する化合物のスクリーニング方法：澤田純一，小澤正吾，埴岡伸光，斎藤嘉朗（特願2001-291004（2001年9月25日出願）；特開2003-93068（2003年4月2日公開）．

競争的資金

府省庁(代表)

• 科学研究費助成事業（基盤研究C），異物代謝酵素の多様性に基づく化学物質のオーダーメイド型リスク評価システムの構築，2023～2025年度．
• 科学研究費助成事業（基盤研究B），異物応答因子を基軸とする生活環境中化学物質の革新的なリスク評価システムの構築，2019～2022年度．
• 科学研究費助成事業（挑戦的研究・萌芽），化学物質の個別化リスク評価法の開発：人工カクテル異物代謝酵素を用いる戦略，2018～2020年度．
• 科学研究費助成事業（基盤研究B），異物代謝酵素に着眼した化学物質の暴露経路依存的なリスク評価法の構築，2014～2016年度．
• 科学研究費助成事業（基盤研究C），異物代謝能の個人差を考慮した化学物質のリスク評価法の開発研究，2011～2013年度．
• 科学研究費助成事業（基盤研究C），化学物質の個別化危険度評価を目指した異物代謝能の個人差発現の解明，2008～2010年度．
• 科学研究費助成事業（基盤研究C），環境汚染物質に対する異物代謝能個人差の分子毒性学的研究，2006～2007年度．
• 厚生科学研究費補助金（特別研究事業），薬物代謝酵素の分子多様性に基づくハイテク汚染物質の生体影響評価法の開発研究，1996年度．
• 厚生科学研究費補助金（特別研究事業，シトクロムP450を指標とする産業用有機溶剤の健康影響評価に関する研究，1995年度．
• 科学研究費助成事業（奨励研究A），環境汚染物質塩素化エチレン化合物によるP450の変動：その構造活性相関の解明，1995年度．
• 科学研究費助成事業（奨励研究A），ハイテク汚染物質による薬物代謝酵素系の変動に関する研究，1994年度．

財団法人(代表)

• 住友財団・環境研究助成，人工カクテル異物代謝酵素を用いる環境汚染物質のハイスループット毒性評価法の構築，2013年度．

府省庁(分担)

• 厚生労働科学研究費補助金（化学物質リスク研究事業），室内空気環境汚染化学物質の標準試験法の策定およびリスク低減化に関する研究，2018～2020年度．
• 厚生労働科学研究費補助金（化学物質リスク研究事業），気道障害性を指標とする室内環境化学物質のリスク評価手法の開発に関する研究，2015～2017年度．
• 厚生労働科学研究費補助金（政策創薬マッチング研究事業），ヒトにおける安全性確保のための、非臨床・臨床開発における評価・予測系の開発，2012～2013年度．
• 科学研究費助成事業（挑戦的萌芽研究），モルヒネ耐性発現における活性代謝物モルヒノンの役割解明，2012～2014年度．
• 厚生労働科学研究費補助金（政策創薬総合研究事業），医薬品開発のための副作用予測法・評価法の開発，2010～2011年度．
• 厚生労働科学研究費補助金（化学物質リスク研究事業），家庭用品に由来する化学物質の多経路暴露評価手法の開発に関する研究，2009～2011年度．
• 厚生労働科学研究費補助金（政策創薬総合研究事業），ファーマコゲノミクス情報に基づいた医薬品の有効性及び安全性評価系の開発と医薬品開発への応用，2007～2009年度．
• 科学研究費助成事業（萌芽研究），霊長類キメラ酵素を用いた環境中化学物質の代謝に与るグルクロン酸転移酵素の機能解明，2006～2007年度．
• 厚生労働科学研究費補助金（萌芽的先端医療技術技術推進研究事業），インスリン分泌型経口糖尿病薬の薬物応答関連遺伝子の探索及びそのテーラーメイド投薬への応用，2005～2007年度．
• 科学研究費助成事業（基盤研究B），化学物質の毒性評価を目的とした霊長類薬物代謝酵素の比較生化学的研究，2005～2007年度．
• 厚生労働科学研究費補助金（健康科学総合研究事業），化学物質過敏症等室内空気中化学物質に係わる疾病と総化学物質の存在量の検討と要因解明に関する研究，2002～2003年度．
• 産官学連携イノベーション創出事業費補助金，DNAチップを用いた環境汚染物質の遺伝子多型の検索と環境リスク評価に関する研究，2001～2002年度．
• 厚生労働科学研究費補助金（疾病対策・創薬推進研究事業），薬剤反応性遺伝子解析，2000～2002年度．

財団法人(分担)

• 日本食品化学研究振興財団研究助成金，食品容器包装関連化学物質の食品への移行性とリスク評価に関する研究，2006年度．
• 臨床薬理研究振興財団研究奨励金，遺伝子多型性Phase IおよびPhase II薬物代謝酵素を構成要素とした副作用発現予測系の構築，2003年度．